Anti-tumor B for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot use any medicinal botanical, natural, or other herbal compounds while participating in the trial.
What safety data exists for Anti-tumor B (Zeng Sheng Ping) in cancer treatment?
The safety data for Anti-tumor B, also known as Zeng Sheng Ping, is limited in the provided research. The studies primarily focus on its efficacy in cancer prevention and treatment, particularly in inhibiting tumor growth and signaling pathways. However, specific safety data or adverse effects are not detailed in the abstracts provided. Further investigation into clinical trials or detailed studies would be necessary to obtain comprehensive safety data.12345
Is Anti-tumor B a promising drug for cancer?
What data supports the idea that Anti-tumor B for Cancer is an effective treatment?
The available research does not provide specific data supporting the effectiveness of Anti-tumor B for Cancer. Instead, it discusses other treatments and strategies, such as the use of Human Beta Defensin (hBD-1) in breast cancer and the effects of emodin and BTB14431 in colonic cancer. Without specific data on Anti-tumor B, we cannot conclude its effectiveness compared to other treatments.1112131415
Who Is on the Research Team?
Stuart J. Wong, MD
Principal Investigator
Medical College of Wisconsin
Are You a Good Fit for This Trial?
Adults over 18 with a new or recurring oral cavity squamous cell cancer, who haven't had systemic chemotherapy for it. They must be fit for surgery and have good organ function. Women of childbearing age must use contraception, and men agree to barrier methods or abstinence.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take Anti-tumor B, 1,200 mg three times a day, until the evening prior to surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Anti-tumor B
- Placebos
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor